title: [Nephrogenic systemic fibrosis and use of MR contrast media].
abstract: BACKGROUND
  Nephrogenic systemic fibrosis (NSF) is a new and probably iatrogenic disorder. It was first described time in 2000 and associated with the use of gadolinium containing MR contrast media in patients with impaired renal function in 2006.
  
  
  METHODS
  We describe a case of NSF identified at Haukeland University Hospital and give a brief overview of the disease, based on literature retrieved from a non-systematic search.
  
  
  CONCLUSIONS
  NSF is a serious systemic disorder with active inflammation and fibrosis, particularly in skin, but also in other tissue such as skeletal muscle, heart and oesophagus. The condition is very difficult to treat. Awareness of the illness has led to changes in guidelines and clinical practice regarding use of gadolinium-containing contrast media in patients with renal impairment.
authors.affiliation: Medisinsk avdeling Haukeland universitetssykehus 5021 Bergen. rchr@helse-bergen.no
authors.forename: Rolf E F
authors.initials: RE
authors.lastname: Christiansen
authors.forename: Lisbet
authors.initials: L
authors.lastname: Sviland
authors.forename: Ingegjerd
authors.initials: I
authors.lastname: Sekse
authors.forename: Einar
authors.initials: E
authors.lastname: Svarstad
mesh_terms: D000328:Adult; D003287:Contrast Media / Q000009:adverse effects*; D019786:Gadolinium DTPA / Q000009:adverse effects*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000473:pathology; D018810:Magnetic Resonance Angiography; D008297:Male; D054989:Nephrogenic Fibrosing Dermopathy / Q000139:chemically induced* / Q000473:pathology; D012867:Skin / Q000276:immunology / Q000473:pathology
chemical_list: D003287:Contrast Media; C064925:gadodiamide; D019786:Gadolinium DTPA